Cover Image
市場調查報告書

全球抗體、藥物複合體(ADC)市場未來展望

Global Antibody Drug Conjugate Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 297685
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
全球抗體、藥物複合體(ADC)市場未來展望 Global Antibody Drug Conjugate Market Outlook 2020
出版日期: 2015年07月01日 內容資訊: 英文 80 Pages
簡介

抗體、藥物複合體(ADC)不是新奇之物,從1990年代就開始開發了。可是,藥物用有效負載的規格,及抗體和藥物結合困難度的問題,使開發活動不斷起伏變化。可是,由於連接試劑技術和有效負載的功能、規格達成大幅度技術進步,ADC的開發這數年來有飛躍性進展。現在,Adcetris和Kadcyla這2個產品上市。全球的ADC市場規模,預計2020年達到127億美元。

本報告提供全球的抗體、藥物複合體(以下ADC)市場相關分析、整體產業結構,及已上市產品的市場趨勢、臨床實驗中的主要藥物的概要與今後的開發預測、近幾年的市場、企業趨勢、主要產業促進、阻礙因素、主要企業簡介等調查。

第1章 分析師的見解

第2章 分析方法

第3章 抗體、藥物複合體(ADC):概要

第4章 ADC市場未來展望

  • Adcetris
  • Kadcyla
    • 市場未來性
    • 市場規模與其預測(今後6年份)

第5章 開發平台分析

  • 各階段
  • 各症狀
  • 各藥物

第6章 市場推動因素與課題

  • 推動因素
  • 課題

第7章 開發平台上的潛在ADC現況

  • Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
  • Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
  • Indatuximab Ravtansine/BT-062 - Biotest
  • Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
  • Polatuzumab Vedotin/RG7596 - Roche Genentech
  • Pinatuzumab Vedotin/RG7593 - Roche Genentech
  • Lifastuzumab Vedotin/RG7599 - Roche Genentech
  • Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
  • Inotuzumab Ozogamicin (CMC-544) - Pfizer

第8章 趨勢及發展

  • ADC最尖端的惡性血液疾病治療藥
  • 帶給乳癌患者希望的ADC

第9章 ADC產業的策略性產業聯盟

第10章 競爭環境

  • Seattle Genetics
  • Roche
  • Immunogen, Inc.
  • Bayer Healthcare
  • Novartis
  • Immunomedics
  • Agensys, Inc.

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Antibody drug conjugates are the new age therapeutic agents. These are examples of immunoconjugates and bioconjugates. They combine the unique targeting property of monoclonal antibodies and the cancer cell killing ability of cytotoxic drugs. This concept of a "magic bullet" to deliver cytotoxic therapy to the site of a tumor has been envisioned for a century. But its success has become possible only now with the recent technological advancements. The recent approvals of ADCETRIS and Kadcyla followed by various Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in the ADC industry.

According to this edition of the report "Global Antibody Drug Conjugate Market Outlook 2020", the ADC market is anticipated to reach around US$ 12.7 Billion by 2020. In our report, there is a detailed analysis of the market for ADCETRIS and Kadcyla. An estimation of the market potential of these drugs has been done keeping in mind that these drugs are being tested in clinical trials for various indications, apart from the ones which are already approved. The mentioned ADCs will take some time to show their complete market potential, we believe.

Moreover, in our report we have provided information about the ADCs at various stages of clinical development. We have highlighted the various cancer indications that these ADCs target and the cytotoxic drugs that are commonly used for their development. Apart from this, the study provides comprehensive analysis of various ADCs in advanced stages of development. In addition, the report highlights the major drivers and challenges, latest trends and developments and strategic collaborations impacting the industry's growth.

The latter part of the report discusses some of the prominent players in the ADC market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Moreover, comparative analyses of their strengths and weaknesses have also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2020

  • 4.1 ADCETRIS
    • 4.1.1 Market Potential
    • 4.1.2 Market Size and Forecasts to 2020
  • 4.2 Kadcyla
    • 4.2.1 Market Potential
    • 4.2.2 Market Size and Forecasts to 2020

5. ADC Pipeline Analysis

  • 5.1 By Phase
  • 5.2 By Indication
  • 5.3 By Drug

6. Drivers and Challenges

  • 6.1 Drivers
    • 6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
    • 6.1.2 Efforts towards Patent Protection to Drive ADC Market
  • 6.2 Challenges
    • 6.2.1 Production Hurdles and Cost
    • 6.2.2 Inadequacy of Experienced Manufacturers
    • 6.2.3 Regulatory Challenges

7. Current Status of Potential ADCs in Pipeline

  • 7.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
  • 7.2 Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
  • 7.3 Indatuximab Ravtansine/BT-062 - Biotest
  • 7.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
  • 7.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
  • 7.6 Pinatuzumab Vedotin/RG7593 - Roche Genentech
  • 7.7 Lifastuzumab Vedotin/RG7599 - Roche Genentech
  • 7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
  • 7.9 Inotuzumab Ozogamicin (CMC-544) - Pfizer

8. Trends and Developments

  • 8.1 ADC at the Forefront to Treat Hematological Malignancies
  • 8.2 ADCs Providing Advantages to Breast Cancer Patients

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment

  • 10.1 Seattle Genetics
  • 10.2 Roche
  • 10.3 Immunogen, Inc.
  • 10.4 Bayer Healthcare
  • 10.5 Novartis
  • 10.6 Immunomedics
  • 10.7 Agensys, Inc

List of Figures:

  • Figure 3-1: ADC - Mechanism of Action
  • Figure 4-1: Global - ADC Market (Billion US$), 2014-2020
  • Figure 4-2: Global - ADCETRIS Market (Million US$), 2011-2013
  • Figure 4-3: Global - ADCETRIS Market (Billion US$), 2014-2020
  • Figure 4-4: Global - Kadcyla Market (Billion US$), 2014-2020
  • Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
  • Figure 5-2: Pipeline ADCs by Indication (2014)
  • Figure 5-3: Pipeline ADCs by Drug (2014)

List of Tables:

  • Table 4-1: Potential Patients for ADCETRIS (2012)
  • Table 4-2: Ongoing Trials for ADCETRIS
  • Table 4-3: Potential Patients for Kadcyla (2012)
  • Table 4-4: Ongoing Trials for Kadcyla
  • Table 7-1: ADCs in Pipeline
  • Table 9-1: Strategic Collaborations in ADC Industry
  • Table 10-1: Top Companies by ADCs in Pipeline (2014)
  • Table 10-2: Seattle Genetics - ADCs in Pipeline
  • Table 10-3: Seattle Genetics - ADCs Collaborator Pipeline
  • Table 10-4: Seattle Genetics - Strengths and Weaknesses
  • Table 10-5: Roche - ADC Collaborator Pipeline
  • Table 10-6: Roche - Strengths and Weaknesses
  • Table 10-7: Immunogen, Inc. - ADCs in Pipeline
  • Table 10-8: Immunogen, Inc. - ADC Collaborator Pipeline
  • Table 10-9: Immunogen, Inc. - Strengths and Weaknesses
  • Table 10-10: Bayer Healthcare - ADCs in Pipeline
  • Table 10-11: Bayer Healthcare - Strengths and Weaknesses
  • Table 10-12: Novartis Pharmaceuticals - ADCs in Pipeline
  • Table 10-13: Novartis Pharmaceuticals - Strengths and Weaknesses
  • Table 10-14: Immunomedics - ADCs in Pipeline
  • Table 10-15: Immunomedics - Strengths and Weaknesses
  • Table 10-16: Agensys, Inc. - ADC Collaborator Pipeline
  • Table 10-17: Agensys, Inc. - Strengths and Weaknesses
Back to Top